
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 30, 2017**

Spotlight Innovation Inc.

(Exact name of registrant as specified in its charter)

| | | |
|---|---|---|
| <u>Nevada</u> (State or other jurisdiction of Incorporation) | <u>000-52542</u> (Commission File Number) | <u>98-0518266</u> (IRS Employer Identification No.) |
| <u>11147 Aurora Avenue, Aurora Business Park, Building 3, Urbandale, IA</u> (Address of principal executive offices) | | <u>50322</u> (Zip Code) |

Registrant's telephone number, including area code: **(515) 274-9087**

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8 K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a 12 under the Exchange Act (17 CFR 240.14a 12)
 - Pre commencement communications pursuant to Rule 14d 2(b) under the Exchange Act (17 CFR 240.14d 2(b))
 - Pre commencement communications pursuant to Rule 13e 4(c) under the Exchange Act (17 CFR 240.13e 4(c))
-

Item 8.01 Other Events.

On June 30, 2017, Spotlight Innovation Inc. issued a Press Release announcing that it has engaged PCG Advisory Group as its investor relations firm. A copy of this Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit

[99.1 Press Release dated June 30, 2017.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPOTLIGHT INNOVATION INC.

Dated: June 30, 2017

By: /s/ John William Pim

John William Pim
Chief Financial Officer

EXHIBIT INDEX

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit

99.1 [Press Release dated June 30, 2017.](#)

Spotlight Innovation Engages Investor Relations Firm PCG Advisory Group

URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has engaged PCG Advisory Group (PCG) to provide investor relations services in support of the Company and its drug development programs, and to strengthen its connection to the investment community.

“We are pleased to partner with PCG, a pioneering integrated communications firm, to energize our investor relations activities,” said John Krohn, Spotlight Innovation’s President and Chief Executive Officer. “We believe PCG is well-suited to explain our ongoing efforts to develop novel therapeutic product candidates for rare diseases. Moreover, as we bring to market Venodol, our first over-the-counter analgesic, we consider PCG to be the ideal firm to educate investors about this breakthrough product.”

"Spotlight Innovation has a unique business model and investment story to tell that we believe will resonate on Wall Street and beyond. We look forward to working together to communicate their value proposition to our broad network of investors, bloggers, journalists, and other key stakeholders," said Jeff Ramson, Founder and CEO of PCG.

About PCG Advisory Group

Founded in 2008 and headquartered in New York City, PCG Advisory Group is dedicated to the delivery of top tier investor relations, strategic advisory, communications, and innovative digital media services for the micro and small cap public company marketplace. PCG has extensive experience with life sciences, technology, energy and other emerging growth companies, both in the US and internationally.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Spotlight Innovation Inc.

Press Contact

Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
corpcomm@spotlightinnovation.com

Investor Contact

PCG Advisory Group
Stephanie Prince
sprince@pcgadvisory.com
(646) 762-4518